Press release
Cholangiocarcinoma Market Size was USD 786.1 Million in 2021
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key takeaways from the Cholangiocarcinoma Market Report
• In 2021, the total Cholangiocarcinoma market size was USD 786.1 million which is expected to rise during the study period (2019-2032).
• According to the DelveInsight, in the year 2021, the total diagnosed incident cases of Cholangiocarcinoma were 10,034 in the United States which are expected to grow during the study period, i.e., 2019-2032.
• The highest number of total incident cases of Cholangiocarcinoma was observed in Italy among the EU5 countries with 6,489 cases in 2021 which are expected to grow during the study period, i.e., 2019-2032.
• In the year 2021, the total diagnosed incident cases of Cholangiocarcinoma were 16,004 in Japan which are expected to grow during the study period, i.e., 2019-2032.
• The leading Cholangiocarcinoma Market Companies include AstraZeneca, Decalth Systems, Basilea Pharmaceutical, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and others.
• Promising Cholangiocarcinoma Pipeline Therapies include BGJ398 (infigratinib), Gemcitabine, Cisplatin, CX-4945, E7090, Pemigatinib, Derazantinib, TAS-120, and others.
For more insights into the Cholangiocarcinoma Market Landscape, visit Cholangiocarcinoma Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Recent Developmental Activities in the Cholangiocarcinoma Treatment Landscape
• KEYTRUDA (pembrolizumab) is being developed by Merck is an anti-PD-1 therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. Currently, Keytruda is being evaluated in Phase III (NCT04003636. KEYNOTE-966) clinical trial. This is a study of the combination of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The study is anticipated to complete by November 2024.
• Currently, Zymeworks and BeiGene are co-developing Zanidatamab which is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2, resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function mediated cytotoxicity, enhanced antibody internalization and HER2 downregulation and enhanced blockade of ligand-dependent and ligand-independent tumor growth. Zanidatamab is being evaluated in global Phase II (NCT03929666). The study is anticipated to be complete by April 2024.
• Eisai is currently developing its lead product candidate Tasugratinib (E7090) which is discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3. It has been granted the orphan drug designation with a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare (MHLW) in Japan. Currently, a Phase II (NCT04238715) clinical trial of E7090 is underway in Japan and China to evaluate efficacy and safety in patients with cholangiocarcinoma with FGFR2 gene fusion. The study is anticipated to be complete by September 2023.
Cholangiocarcinoma Epidemiology Segmentation in the 7MM
• Total Cholangiocarcinoma Diagnosed-incidence Cases
• Total Cholangiocarcinoma Type-specific Cases
• Total Cholangiocarcinoma Age-specific Cases
• Total Cholangiocarcinoma Stage-specific Cases
• Total Cholangiocarcinoma Mutation-specific Cases
• Total Cholangiocarcinoma Treated Cases (across lines)
To know more information of the Cholangiocarcinoma Epidemiology Segmentation of the report, click here for Cholangiocarcinoma Epidemiology Insights @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cholangiocarcinoma Market Insight
Photodynamic therapy can improve survival in patients with unresectable BTC. The role of radiation therapy in BTC is still not clearly outlined, but radiation with concurrent chemotherapy has been recommended in margin-positive and node-positive iCCA and pCCA, and unresectable pCCA is ineligible for liver transplantation
Cholangiocarcinoma Emerging Drugs
• LYTGOBI (futibatinib)
• TIBSOVO (ivosidenib)
• TRUSELTIQ (infigratinib)
• PEMAZYRE (pemigatinib)
• TT-00420 (TransThera Sciences, Phase II)
• KEYTRUDA (pembrolizumab) (Merck Sharp & Dohme, Phase III)
Browse More Related Reports of the Cholangiocarcinoma Market Research Reports, click here for Cholangiocarcinoma Market Forecast @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Cholangiocarcinoma Market Report
• Coverage- 7MM
• Cholangiocarcinoma Companies- AstraZeneca, Decalth Systems, Basilea Pharmaceutical, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and others.
• Cholangiocarcinoma Pipeline Therapies- BGJ398 (infigratinib), Gemcitabine, Cisplatin, CX-4945, E7090, Pemigatinib, Derazantinib, TAS-120, and others.
• Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma Market Drivers and Barriers
• Cholangiocarcinoma Market Access and Reimbursement, Unmet Needs, Future Perspectives
Read the Full Research Report of the Cholangiocarcinoma Market Forecast Report, click here for Cholangiocarcinoma Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Executive Summary of Cholangiocarcinoma (CCA)
3. Cholangiocarcinoma (CCA) Market Overview at a Glance
4. Cholangiocarcinoma (CCA): Disease Background and Overview
5. Treatment
6. Epidemiology and Patient Population
7. United States Epidemiology
8. EU5 Epidemiology
9. Japan Epidemiology
10. Patient Journey
11. Key endpoints in Cholangiocarcinoma trials
12. Marketed Cholangiocarcinoma Drugs
13. Emerging Cholangiocarcinoma Therapies
14. Conjoint Analysis
15. Cholangiocarcinoma (CCA): 7MM Market Analysis
16. Cholangiocarcinoma Market Access and Reimbursement
17. KOL views
18. Cholangiocarcinoma Market Drivers
19. Cholangiocarcinoma Market Barriers
20. SWOT Analysis
21. Cholangiocarcinoma Unmet needs
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
Consult with our Business Expert @ Cholangiocarcinoma Market Landscape- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cholangiocarcinoma Market Size was USD 786.1 Million in 2021 here
News-ID: 2978053 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Cholangiocarcinoma
Cholangiocarcinoma Market to Reach USD 2.87 Billion by 2034
The global cholangiocarcinoma market is positioned for steady growth, driven by increasing awareness, improved diagnostic capabilities, and the expanding approval of targeted drugs. Between 2024 and 2034, a combination of innovative drug pipelines, biomarker-based diagnostics, and supportive policy frameworks is expected to transform patient outcomes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70843
Market Overview
• Market Size (2024): USD 1.32 billion
• Forecasted Market Size (2034): USD 2.87 billion
• CAGR (2024-2034): ~8.1%
• Key Drivers: Genomic…
Cholangiocarcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2024" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cholangiocarcinoma Pipeline Report
• DelveInsight's Cholangiocarcinoma pipeline…
Cholangiocarcinoma Market Size was USD 786.1 million in 2021
The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032…
Global Cholangiocarcinoma Market
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Overview by Advance Technology, Future Outlook 2032
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Therapeutics Market Dynamic Demand by 2028
Global Cholangiocarcinoma Therapeutics Market: Overview
Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. However, some of the factors…
